Amgen, Novartis May Screen 30,000 Patients To Find 2,000 For Alzheimer's Trial

A new trial for CNP520 will see if the Amgen/Novartis BACE1 inhibitor can prevent, stop or slow Alzheimer's disease progression in pre-symptomatic patients, but recruiting enough patients with the APOE4 gene will require a massive screening effort.